pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX
CATALYST PHARMACEUTICALS
CATALYST PHARMACEUTICALS, INC.
CATALYST PHARMACEUTICALS clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
- Founded
- 2002
- Employees
- 179
- Programs
- 23
- Drugs
- 20
- Patents
- 61
CATALYST PHARMACEUTICALS projects
7 ClinicalTrials.gov programs sponsored by CATALYST PHARMACEUTICALS.
CATALYST PHARMACEUTICALS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Airway Bypass
CATALYST PHARMACEUTICALS, INC.
Emphysema or COPD
1 trial -
Bumetanide
CATALYST PHARMACEUTICALS, INC.
Seizures
1 trial -
CPP-115
CATALYST PHARMACEUTICALS, INC.
Cocaine Dependency
1 trial -
HWK-016, MUCIN-16-targeted ADC
CATALYST PHARMACEUTICALS, INC.
PROC
1 trial -
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
CATALYST PHARMACEUTICALS, INC.
Hemophilia B
1 trial -
MarzAA (marzeptacog alfa [activated])
CATALYST PHARMACEUTICALS, INC.
Hemophilia A
1 trial -
PF-05280602
CATALYST PHARMACEUTICALS, INC.
Hemophilia A
1 trial
Frequently asked questions
How many clinical projects does CATALYST PHARMACEUTICALS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.